慢性乙型肝炎患者血清suPAR和IP-1O水平及其临床意义

doi:10.3969/j.issn.1672-5069.2017.03.022

Abstract

Zhao Yuan, Cao Weizhang, Fang Rong, et al.. Clinical significance of serum suPAR and IP-10 levels in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 345-346.

[1] Castera L.Hepatitis B:are non-invasive markers of liver fibrosis reliable Liver Int,2014,34(suppl 1):91-96.
[2] 刘婷,徐铭益. 肝纤维化的血清学诊断研究进展. 实用肝脏病杂志,2016,19(1):125-128.
[3] Berres ML,Schlosser B,Berg T,et al.Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis infection. J Clin Gastroenterol,2012,46(4):334-338.
[4] You CR,Park SH,Jeong SW,et al.Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver,2011,5(40):506-512.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89.
[6] 中华医学会传染病与寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案. 中华传染病杂志,2001,19(1):56-62.
[7] Imperiale TF,Said AT,Cummings OW,et al.Need for validation of clinical decision aids:use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am [J] Gastroenterol. 2000,95:2328-2332.
[8] Wai CT,Greenson JK,Fontana RJ,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology,2003,38:518-526.
[9] Ebrahimi H,Naderian M,Sohrabpour AA.New concepts on pathogenesis and diagnosis of liver fibrosis. Middle East J Dig Dis,2016,8(3):166-178.
[10] Chounta A,Ellinas C,Tzanetakou V,et al.Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Liver Int,2015,35:601-607.
[11] Chen LJ,Lyu J,Wen XY,et al.CXC chemokine IP-10:a key actor in liver disease Hepatol Int,2013,7(3):798-804.
[12] 杨华,罗亚文,刘华庆,等. 慢性乙型肝炎患者肝组织CXCR3及其配体IP10表达与肝脏炎症程度、纤维化的相关性研究. 第三军医大学学报,2012,34(3):250-253.
[13] 赵亚娟,赵彩彦,王亚东. 干扰素γ诱导蛋白-10与慢性乙型肝炎肝纤维化发生发展相关性研究. 现代中西医结合杂志,2016,25(15):1623-1626.
[14] Ceylan B,Fincanci M,Yardimci C,et al.Can mean platelet volume determine the severity of liver fibrosis or inflammation in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol,2013,25(5):606-612.
[15] 刘红波,白菡,梁彬. 用ROC曲线判断慢性乙肝患者谷草转氨酶和血小板比值与肝纤维化程度的关系. 中国现代医学杂志,2007,24(12):3050-3052.

Clinical significance of serum suPAR and IP-10 levels in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[10]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[13]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[14]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[15]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.